Satsuma Pharmaceuticals (NASDAQ: STSA)
Some price data may be temporarily unavailable.
Satsuma Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Satsuma Pharmaceuticals Company Info
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC.
News & Analysis
Why Satsuma Pharmaceuticals Stock Is Plummeting Today
Investors are reeling from a late-stage flop for the company's only pipeline candidate.
2 Small-Cap Stocks That Could Double Your Money
Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.